Research Analysts Set Expectations for Foghorn Therapeutics Inc.'s Q1 2025 Earnings (NASDAQ:FHTX)

Foghorn Therapeutics Inc. (NASDAQ:FHTX - Free Report) - Equities researchers at Wedbush issued their Q1 2025 EPS estimates for Foghorn Therapeutics in a research report issued to clients and investors on Monday, May 6th. Wedbush analyst R. Driscoll expects that the company will earn ($0.36) per share for the quarter. Wedbush has a "Outperform" rating and a $13.00 price target on the stock. The consensus estimate for Foghorn Therapeutics' current full-year earnings is ($2.05) per share. Wedbush also issued estimates for Foghorn Therapeutics' Q2 2025 earnings at ($0.37) EPS, Q3 2025 earnings at ($0.33) EPS and Q4 2025 earnings at ($0.30) EPS.

Separately, HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Foghorn Therapeutics in a research note on Tuesday.

Foghorn Therapeutics Trading Up 6.2 %

Shares of NASDAQ:FHTX traded up $0.35 during trading on Wednesday, hitting $5.98. 55,696 shares of the company were exchanged, compared to its average volume of 138,351. The stock has a market cap of $254.57 million, a price-to-earnings ratio of -2.39 and a beta of 3.15. Foghorn Therapeutics has a fifty-two week low of $2.70 and a fifty-two week high of $9.97. The firm has a fifty day moving average price of $6.41 and a two-hundred day moving average price of $5.35.

Foghorn Therapeutics (NASDAQ:FHTX - Get Free Report) last released its earnings results on Thursday, March 7th. The company reported ($0.57) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.79) by $0.22. The company had revenue of $5.77 million during the quarter, compared to analyst estimates of $4.91 million.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Raymond James & Associates increased its holdings in shares of Foghorn Therapeutics by 19.8% in the third quarter. Raymond James & Associates now owns 1,426,226 shares of the company's stock valued at $7,131,000 after purchasing an additional 235,237 shares during the last quarter. Nisa Investment Advisors LLC raised its holdings in Foghorn Therapeutics by 788.1% in the 4th quarter. Nisa Investment Advisors LLC now owns 5,000 shares of the company's stock valued at $32,000 after acquiring an additional 4,437 shares during the period. Exchange Traded Concepts LLC lifted its position in Foghorn Therapeutics by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 21,535 shares of the company's stock worth $139,000 after acquiring an additional 5,460 shares during the last quarter. Panagora Asset Management Inc. bought a new stake in shares of Foghorn Therapeutics during the third quarter worth approximately $173,000. Finally, Birchview Capital LP grew its position in shares of Foghorn Therapeutics by 21.2% in the fourth quarter. Birchview Capital LP now owns 320,930 shares of the company's stock valued at $2,070,000 after purchasing an additional 56,087 shares during the last quarter. 61.55% of the stock is owned by institutional investors and hedge funds.

Foghorn Therapeutics Company Profile

Foghorn Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.